ProCE Banner Activity

Call to Action: Misperceptions on TROP2-Targeted Antibody–Drug Conjugates in Lung Cancer

Clinical Thought

In this commentary, Stephen Liu, MD, reflects on key misperceptions revealed by a survey of oncology healthcare professionals on emerging TROP2-targeted antibody–drug conjugates for the treatment of patients with lung cancer, including how these agents work, how well they work, and how to identify patient candidates.

Released: February 24, 2023

Expiration: February 23, 2024

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Disclosure

Stephen Liu, MD: consultant/advisor: AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Catalyst, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche, Gilead, Guardant Health, Janssen, Jazz, Merck, Merus, Novartis, Regeneron, Sanofi, Takeda, Turning Point Therapeutics; researcher (paid to institution): Alkermes, Elevation Oncology, Genentech, Gilead, Merck, Merus, Nuvalent, RAPT, Turning Point Therapeutics; data and safety monitoring board: Candel Therapeutics.